1204669-57-7

Basic information

• Product Name: 3-(4-(2-aMinoethylaMino)-1,2,5-oxadiazol-3-yl)-4-(3-broMo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydroiodide
• Synonyms: 3-(4-(2-aMinoethylaMino)-1,2,5-oxadiazol-3-yl)-4-(3-broMo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydroiodide;3-(4-(2-AMINOETHYLAMINO)-1,2,5-OXADIAZOL-3-YL)-4-(3-BROMO-4-FLUOROPHENYL)-1,2,4-OXADIAZOL-5(4H)-ONE HI
• CAS NO: 1204669-57-7
• Molecular Formula: C₁₂H₁₀BrFN₆O₃*HI
• Molecular Weight: 513.0610132
• Mol File: 1204669-57-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-(2-aMinoethylaMino)-1,2,5-oxadiazol-3-yl)-4-(3-broMo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydroiodide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-(2-aMinoethylaMino)-1,2,5-oxadiazol-3-yl)-4-(3-broMo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydroiodide(1204669-57-7)
• EPA Substance Registry System: 3-(4-(2-aMinoethylaMino)-1,2,5-oxadiazol-3-yl)-4-(3-broMo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydroiodide(1204669-57-7)

Safety Data

• Hazardous Substances Data: 1204669-57-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-(2-Aminoethylamino)-1,2,5-oxadiazol-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one hydroiodide is used as a reactant in the synthesis of indoleamine dioxygenase/histone deacetylase dual inhibitors. These inhibitors play a crucial role in regulating cellular processes and have potential therapeutic applications in the treatment of various diseases, including cancer and neurodegenerative disorders. The compound's unique structure allows it to interact with specific targets, making it a valuable component in the development of novel drugs.

Upstream product

• 1204669-66-8 3-(4-((2-azidoethyl)amino)-1,2,5-oxadiazole-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazole-5(4H)-one 
• 1204669-63-5 4-(3-bromo-4-fluorophenyl)-3-{4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl}-1,2,4-oxadiazol-5(4H)-one 
• 1204669-64-6 4-(3-bromo-4-fluorophenyl)-3-{4-[(2-hydroxyethyl)amino]-1,2,5-oxadiazol-3-yl}-1,2,4-oxadiazol-5(4H)-one 
• 1204669-65-7 2-({4-[4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-yl}amino)ethyl methanesulfonate 
• 1204669-59-9 4-amino-N‘-hydroxy-N-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-60-2 N¹-hydroxy-4-((2-methoxyethyl)amino)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-61-3 N-hydroxy-4-[(2-methoxyethyl)amino]-1,2,5-oxadiazole-3-carboximidoyl chloride 
• 1204669-62-4 N-(3-bromo-4-fluorophenyl)-N‘-hydroxy-4-((2-methoxyethyl)amino)-1,2,5-oxadiazole-3-carboximidamide 

Relevant articles and documents

INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION

The present invention relates to an indoleamine 2,3-dioxygenase inhibitor having the structure of formula (I), a preparation method therefor, and an application. The IDO inhibitor is an N′-hydroxyl-N-phenylformamidine derivative, which has a high inhibito

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors

In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed. The highly active dual inhibitor 10 showed exc

1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.

1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE

The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.